NEXGEL, Inc. (NXGLW) Aandelenanalyse

Bedrijfsoverzicht

NEXGEL, Inc. is engaged in the manufacturing and commercialization of high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels specifically designed for applications in wound care, medical diagnostics, transdermal drug delivery, and the cosmetics sector within the United States market. The company operates within the broader healthcare and consumer goods sectors, although specific sector and industry classifications are currently not disclosed in available data, which places the entity in a specialized niche of medical and cosmetic product development. In terms of operational scale, NEXGEL, Inc. employs 19 individuals and reports a trailing twelve-month revenue of $11.42M, while its market capitalization is not available for public reference. The combination of a modest workforce and a specific product focus suggests a mid-sized, specialized manufacturer that relies on high-margin technical products rather than mass-market volume sales to generate its operational footprint. The absence of a disclosed market cap figure indicates that valuation is likely driven by asset value or cash flow potential rather than traditional earnings multiples, positioning the company as a speculative growth or turnaround candidate within the medical device supply chain.

Financiële gezondheid

The financial performance of NEXGEL, Inc. is characterized by a trailing twelve-month revenue of $11.42M, which is offset by a net income loss of $-3,000,000 and an EBITDA loss of $-2,902,000, revealing a significant gap between top-line generation and bottom-line profitability. This substantial discrepancy between revenue and net income highlights a cost structure where operating expenses and depreciation are consuming nearly the entire revenue stream, resulting in an operating margin of -43.4% and a profit margin of -26.3%. While the gross margin stands at 39.5%, indicating that the core manufacturing process retains a healthy portion of revenue after cost of goods sold, the negative operating and profit margins demonstrate that overhead costs and research and development expenditures are exceeding gross profits. The company's liquidity position is constrained by a free cash flow of $-1,099,250, which signifies a continuous burn rate that limits financial flexibility and necessitates ongoing capital injection or cost reduction measures to achieve solvency. On the balance sheet, the company holds $317,000 in cash against total debt obligations of $3.09M, resulting in a debt-to-equity ratio of 63.14, which indicates a highly leveraged financial structure relative to its equity base. Despite the high leverage, the current ratio of 1.47 suggests that the company maintains a conservative short-term liquidity position, as current assets are 1.47 times greater than current liabilities, providing a buffer against immediate obligations. Return on equity is reported at -52.7% and return on assets at -19.5%, metrics that reveal that management is currently unable to generate positive returns on the capital invested by shareholders or utilized in the company's asset base.

Waarderingsbeoordeling

Valuation multiples for NEXGEL, Inc. are largely unavailable, as the trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that traditional earnings-based valuation methods cannot be applied due to the company's consistent losses and negative earnings trajectory. The price-to-book ratio is recorded at 0.08, a figure that indicates the market is valuing the company at significantly less than the book value of its assets, suggesting that the market price reflects the risks associated with its high debt load and negative earnings. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not available, meaning investors cannot assess the company's value relative to its sales volume or enterprise earnings without relying solely on asset-backed or speculative pricing models. Regarding price volatility and trading range, the 52-week high and low are both recorded at $0.05, meaning the stock is currently trading at 0% below the 52-week high and 0% above the 52-week low, effectively trading within a flat range with no price movement over the past year. The beta value of 0.85 indicates that the stock's price volatility is 15% lower than the broader market, suggesting that the stock is less sensitive to general market movements but remains heavily influenced by specific company events or sector developments.

Growth & Income

The growth profile of NEXGEL, Inc. is currently negative, with revenue growth year-over-year declining by -8.1%, while earnings growth is not applicable due to the company's ongoing losses. The fact that earnings growth is N/A while revenue is contracting suggests that the decline in sales is likely exacerbating the existing cost structure issues, preventing any path toward profitability. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A, which confirms that the company reinvests its limited cash flow, if any, back into operations rather than distributing income to shareholders. The overall growth and income profile presents a challenging scenario where the company is shrinking in revenue, burning cash, and generating negative returns, indicating a need for significant operational turnaround or a strategic pivot to stabilize the business model.